Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
BETOPTIC 0.25% w/v Eye Drops, Suspension.
| Pharmaceutical Form |
|---|
|
Eye Drops, Suspension. |
Betaxolol 0.25% w/v (as hydrochloride).
Excipients with known effect: 1ml of suspension contains 0.1mg benzalkonium chloride.
For a full list of excipients see Section 6.1.
| Active Ingredient |
|---|
|
Betaxolol is a cardioselective Beta1 receptor blocker which, when applied topically to the eye, lowers intraocular pressure. It is thought to produce this effect by reducing the rate of production of aqueous humour. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
BETOPTIC SUSPENSION is packaged as a 5 ml label fill in a 5 ml and a 10 ml label fill in a 10 ml natural low density polyethylene (LDPE), DROP-TAINER with a LDPE dispensing plug and a 15 mm white polypropylene closure. The DROP-TAINER utilizes a tamper evident closure with a breakaway ring.
Novartis Pharmaceuticals UK Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
PL 00101/0990
Date of first authorisation: 27 August 1997
Date of renewal: 27 August 2002
| Drug | Countries | |
|---|---|---|
| BETOPTIC | Austria, Australia, Brazil, Canada, Estonia, Spain, Finland, France, Hong Kong, Croatia, Japan, Lithuania, Malta, Mexico, Nigeria, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.